Core Viewpoint - The announcement highlights a strategic partnership between Majeton Pte Ltd, a wholly-owned subsidiary of 亿胜生物科技 (Yisheng Biotechnology), and Osteopore International Pte Ltd, focusing on exclusive distribution of innovative dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau [1]. Group 1: Partnership Details - Majeton has been appointed as the exclusive distributor for Osteopore's products in the specified regions [1]. - The expected contract value of the distribution agreement exceeds RMB 12,000,000, which includes advance payments and milestone payments [1]. - Additional revenue can be generated through product procurement and supply [1]. Group 2: Market Impact - The collaboration marks a significant milestone for the company in the oral market [1]. - It expands the company's product line in dental, orthodontic, and maxillofacial solutions [1]. - The partnership is aimed at supporting the company's pursuit of sustainable growth in the Chinese market [1].
亿胜生物科技(01061.HK)：附属Majeton获Osteopore独家分销权